Yale Center for Immuno-Oncology
The Yale Center for Immuno-Oncology was established in 2018 to build on Yale Cancer Center’s international leadership in immunology, immunobiology, and the development of innovative cancer immunotherapies. The Center is a partnership between Yale Cancer Center and the Department of Immunobiology at Yale School of Medicine.
The goals for the Yale Center for Immuno-Oncology (YCIO) include to:
- Leverage Yale leadership in immunobiology and immunotherapy drug development.
- Develop the next generation of immune-based therapies.
- Genetically engineer immune cells to target a patient’s cancer (cell therapies).
“This new center gives us the chance to work more collaboratively and efficiently with our world-renowned scientists and faculty to address scientific questions in Immuno-Oncology,” said Roy S. Herbst, MD, PhD, chief of Medical Oncology at YCC, and interim director of YCIO. “We hope we can transform the way we treat people affected by cancer by generating research advances more quickly in this groundbreaking field.”
